Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 19/20 | 0.72 |
| ▸ | WNT3A | P56704 | 18/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15979757 | 0.85 | CTNNB1 (0.86) | CTNNB1WNT3A | |
| SCHEMBL15969099 | 0.84 | CTNNB1 (1.00) | CTNNB1WNT3A | |
| SCHEMBL15979772 | 0.83 | CTNNB1 (0.70) | CTNNB1WNT3AGAA | |
| SCHEMBL15980064 | 0.81 | CTNNB1 (0.57) | CTNNB1WNT3A | |
| SCHEMBL15979771 | 0.80 | MMP1 (0.52) | CTNNB1WNT3A | |
| SCHEMBL21441057 | 0.80 | CTNNB1 (0.48) | CTNNB1WNT3ALMNAGAA | |
| SCHEMBL15979781 | 0.80 | CTNNB1 (0.66) | CTNNB1WNT3ALMNAGAA | |
| SCHEMBL15979770 | 0.80 | CTNNB1 (0.58) | CTNNB1WNT3ALMNA | |
| SCHEMBL15979774 | 0.78 | CTNNB1 (0.60) | CTNNB1WNT3ALMNA | |
| SCHEMBL30089582 | 0.78 | CTNNB1 (0.75) | CTNNB1WNT3ALMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11839679-B2 | Gamma-diketones for treatment and prevention of aging skin and wrinkles | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-11839679-B2 | Gamma-diketones for treatment and prevention of aging skin and wrinkles | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-11673885-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673885-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230053726-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2023-02-23 | — | — | US | disclosed |
| US-20220087917-A1 | GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2022-03-24 | — | — | US | disclosed |
| US-11077046-B2 | Gamma-diketones for treatment and prevention of aging skin and wrinkles | BIOSPLICE THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-11034682-B2 | Gamma-diketones as wnt/β-catenin signaling pathway activators | SAMUMED, LLC (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200222295-A1 | GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES | MED-PATHWAYS II LIMITED (VG) | 2020-07-16 | — | — | US | disclosed |
| US-20200223834-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | MED-PATHWAYS II LIMITED (VG) | 2020-07-16 | — | — | US | disclosed |
| US-9951053-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | SAMUMED, LLC (US) | 2018-04-24 | — | — | US | disclosed |
| US-9795550-B2 | Gamma-diketones for treatment and prevention of aging skin and wrinkles | SAMUMED, LLC (US) | 2017-10-24 | — | — | US | disclosed |
| US-9795550-B2 | Gamma-diketones for treatment and prevention of aging skin and wrinkles | SAMUMED, LLC (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170260176-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | MED-PATHWAYS II LIMITED (VG) | 2017-09-14 | — | — | US | disclosed |
| US-20170260176-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | MED-PATHWAYS II LIMITED (VG) | 2017-09-14 | — | — | US | disclosed |
| US-9533976-B2 | γ-diketones as WNT/β-catenin signaling pathway activators | SAMUMED, LLC (US) | 2017-01-03 | — | — | US | disclosed |
| US-20160206540-A1 | GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2016-07-21 | — | — | US | disclosed |
| US-20160206540-A1 | GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2016-07-21 | — | — | US | disclosed |
| US-20140243349-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2014-08-28 | — | — | US | disclosed |
| WO-2014130869-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | SAMUMED, LLC (US) | 2014-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11077046-B2 | Gamma-diketones for treatment and prevention of aging skin and wrinkles | GLA, DGKG, DGKA | CTNNB1 1789/4885WNT3A 1618/4885LMNA 171/4885 |
| US-20200223834-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | GSK3A, GSK3B, WNT1 | CTNNB1 6/4885WNT3A 4/4885LMNA 1455/4885 |
| US-20220087917-A1 | GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES | GLA, DGKG, DGKA | CTNNB1 1789/4885WNT3A 1618/4885LMNA 171/4885 |
| US-20200222295-A1 | GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES | GLA, DGKG, DGKA | CTNNB1 1789/4885WNT3A 1618/4885LMNA 171/4885 |
| US-20170260176-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | GSK3A, GSK3B, WNT1 | CTNNB1 6/4885WNT3A 4/4885LMNA 1455/4885 |
| US-20160206540-A1 | GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES | GLA, DGKG, DGKA | CTNNB1 1789/4885WNT3A 1618/4885LMNA 171/4885 |
| US-11839679-B2 | Gamma-diketones for treatment and prevention of aging skin and wrinkles | DGKG, DGKA, DNER | CTNNB1 1475/4885WNT3A 1983/4885LMNA 308/4885 |
| US-20230053726-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | GSK3A, GSK3B, WNT1 | CTNNB1 6/4885WNT3A 4/4885LMNA 1455/4885 |
| US-11034682-B2 | Gamma-diketones as wnt/β-catenin signaling pathway activators | GSK3A, GSK3B, WNT1 | CTNNB1 6/4885WNT3A 4/4885LMNA 1468/4885 |
| US-20140243349-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | GSK3A, GSK3B, WNT1 | CTNNB1 6/4885WNT3A 4/4885LMNA 1455/4885 |
| US-11673885-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | GSK3A, GSK3B, WNT1 | CTNNB1 5/4885WNT3A 4/4885LMNA 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.